Functional Genetics (FG) is a development-stage biotechnology company engaged in the development of new therapeutics and diagnostic tools for the treatment of infectious disease, Alzheimer's disease, cancer and other human diseases. Presently, the company has several drug candidates in preclinical development, including a novel antiviral inhibitor shown to reduce the spread of HIV and other viruses in preclinical studies. The company's products facilitate simultaneous targeting of multiple co-morbid pathogens with a single drug. Examples include targeting of distinct respiratory viruses (RSV, PIV, influenza), hepatitis viruses (HBV, HCV), sexually-transmitted diseases (HIV, Herpes) or biothreat (Ebola, Marburg) agents.
